Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HydraMed is a preservative-free ophthalmic lubricant containing 0.2% sodium hyaluronate, developed by Farmigea for the treatment of dry eye disease. The formulation is specifically engineered with a high molecular weight sodium hyaluronate that exhibits non-Newtonian rheological behavior. This property allows the drops to have low viscosity during blinking to minimize friction and high viscosity between blinks to enhance tear film stability and ocular surface retention. By mimicking the natural mucin layer of the tear film and interacting with CD44 receptors on the ocular surface, HydraMed provides long-lasting hydration and protection to the corneal and conjunctival epithelium, alleviating symptoms of ocular dryness and irritation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HydraMed.